Replies to post #121249 on Biotech Values

[10nisman]

Thanks investorgold, my mistake. I mean T-enox Revenue not Mnta-Revenue. MNTA-Revenue will be 94 Mio.

WTH are you talking about? T-enox? Teva's generic version of Lovenox has NOT been approved and thus they will not be earning any revenue in Q2. Also, your revenue estimate for Momenta of $94 million is wildly aggressive, IMHO.